Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-5-27
pubmed:abstractText
The alpha1-adrenoceptor agonist methoxamine acted independently of receptor activation to reduce Ito and the sustained outward current in rat ventricular myocytes, and hKv 1.5 and Kv 4.2 cloned K+ channel currents. Two hundred microM methoxamine reduced Ito by 36% in the presence of 2 microM prazosin, and by 37 and 38% after preincubation of myocytes with either N-ethylmaleimide or phenoxybenzamine (n=6). The EC50 values at +60 mV for direct reduction of Ito, hKv 1.5, and Kv 4.2 by methoxamine were 239, 276, and 363 microM, respectively, with Hill coefficients of 0.87-1.5. Methoxamine accelerated Ito and Kv 4.2 current inactivation in a concentration- and voltage-dependent manner. Apparent rate constants for methoxamine binding and unbinding gave Kd values in agreement with EC50 values measured from dose-response relations. The voltage-dependence of block supported charged methoxamine binding to a putative intracellular site that sensed approximately 20% of the transmembrane electrical field. In the presence of methoxamine, deactivating Kv 4.2 tail currents displayed a distinct rising phase, and were slowed relative to control, such that tail current crossover was observed. These observations support a dominant mechanism of open channel block, although closed channel block could not be ruled out. Single-channel data from hKv 1.5 patches revealed increased closed times with blank sweeps and decreased burst duration in the presence of drug, and a reduction of mean channel open time from 1.8 ms in control to 0.4 ms in 500 microM methoxamine. For this channel, therefore, both open and closed channel block appeared to be important mechanisms for the action of methoxamine.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1323437, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1334487, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1538710, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1667803, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1865177, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1974922, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-1983124, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-2001794, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-2154551, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-2172239, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-2903506, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-4541078, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7517498, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7614722, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7641327, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7911253, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7923290, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-7969082, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8169853, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8222078, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8461140, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8508531, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8620611, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8720476, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8772694, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8831489, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-8913370, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-9118489, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-9130163, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-9190860, http://linkedlifedata.com/resource/pubmed/commentcorrection/10188969-9524137
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Ethylmaleimide, http://linkedlifedata.com/resource/pubmed/chemical/KCNA5 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Kcna5 protein, rat, http://linkedlifedata.com/resource/pubmed/chemical/Kv1.5 Potassium Channel, http://linkedlifedata.com/resource/pubmed/chemical/Methoxamine, http://linkedlifedata.com/resource/pubmed/chemical/Phenoxybenzamine, http://linkedlifedata.com/resource/pubmed/chemical/Phenylephrine, http://linkedlifedata.com/resource/pubmed/chemical/Potassium Channels, http://linkedlifedata.com/resource/pubmed/chemical/Potassium Channels, Voltage-Gated, http://linkedlifedata.com/resource/pubmed/chemical/Prazosin, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, alpha, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Shal Potassium Channels
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
595-606
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:10188969-Adrenergic alpha-Agonists, pubmed-meshheading:10188969-Adrenergic alpha-Antagonists, pubmed-meshheading:10188969-Animals, pubmed-meshheading:10188969-Cell Line, pubmed-meshheading:10188969-Cloning, Molecular, pubmed-meshheading:10188969-Dose-Response Relationship, Drug, pubmed-meshheading:10188969-Electric Stimulation, pubmed-meshheading:10188969-Enzyme Inhibitors, pubmed-meshheading:10188969-Ethylmaleimide, pubmed-meshheading:10188969-Heart Ventricles, pubmed-meshheading:10188969-Humans, pubmed-meshheading:10188969-Kv1.5 Potassium Channel, pubmed-meshheading:10188969-Male, pubmed-meshheading:10188969-Membrane Potentials, pubmed-meshheading:10188969-Methoxamine, pubmed-meshheading:10188969-Myocardium, pubmed-meshheading:10188969-Phenoxybenzamine, pubmed-meshheading:10188969-Phenylephrine, pubmed-meshheading:10188969-Potassium Channels, pubmed-meshheading:10188969-Potassium Channels, Voltage-Gated, pubmed-meshheading:10188969-Prazosin, pubmed-meshheading:10188969-Rats, pubmed-meshheading:10188969-Receptors, Adrenergic, alpha, pubmed-meshheading:10188969-Recombinant Fusion Proteins, pubmed-meshheading:10188969-Shal Potassium Channels, pubmed-meshheading:10188969-Ventricular Function
pubmed:year
1999
pubmed:articleTitle
Non-specific action of methoxamine on Ito, and the cloned channels hKv 1.5 and Kv 4.2.
pubmed:affiliation
Department of Physiology, Queen's University Kingston, Ontario, Canada.
More...